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ABSTRAK 
PEGGUNAAN ROPIV ACAIN DAN BUPIV ACAIN DIDALAM BIUS 
SUPRAKLAVIKULAR BRAKIAL PLEKSUS 
AP AKAH PERBEZAANNY A? 
x 
Satu kajian intervensi yang memakan masa satu tahun dua bulan telah diadakan kepada 
pesakit-pesakit yang menjalani pembedahan anggota atas di Hospital Sains Malaysia, Kubang 
Kerian. Ia adalah satu kajian perbandingan antara dua ubat bius setempat, ropivacain dan 
bupivacain untuk blok supraklavikular braldal pleksus. 
Bius penuh sebenarnya tidak sWlyi dari kompIikasi. Kajian yang berterusan untuk 
mencari ubat bius setempat yang terbaik adalah sangat penting bagi mengelakkan masalah 
kehilangan darah, vena dalaman yang tersumbat, komplikasi pam-pam sesudah pembedahan 
dan keadaan konfusi bagi orang tua. 
Kajian in pada mulanya mengandungi 64 pesakit. 4 pesakit terpaksa dibuang dati 
kajian kerana gagal diblok dan juga masalah keresahan. Pesakit-pesakit ini telah menjalani 
pelbagai jenis pembedaban anggota atas dari Ihb November 1999 bingga 31hb Disember 
2000. mereka telah dimasukkan samada di wad ortopedik atau wad pembedahan. 
Kesemua mereka telah menjalani bius supraklavikular brakial pleksus yang telah 
distandadkan menggunakan kaedah klasik dengan bantuan stimulasi saraf Mereka kemudian 
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diperhatikan, pennulaan sensasi dan motor hilang, jangkamasa bius serta perubahan tanda-
tanda vital. Komplikasi yang lain juga diperhatikan. 
Kajian telah mendapati bahawa, permulaan rasa sakit hilang, permulaan rasa tidak 
sakit sepenubnya dan pennulaan rasa kebas a~lah lebih cepat bagi ropivacain dan adalah 
signifikan dari segi statistik. Pennulaan rasa sakit hilang adalah juga lebih cepat dari 
pennulaan pemblokan motor. Ini membuktikan bahawa ajen ini lebih suka memasuki saraf 
sakit dari saraf motor. Tetapi kajian ini gagaJ mendapati perbezaan didalam permulaan 
pemblokan motor diantara kedua ajen jangkamasa bius. Walaubagaimanapun, jangkamasa 
bius ( pennulaan rasa sakit, pennulaan rasa sakit yang teruk, permulaan rasa kebas hilang dan 
jangkamasa kepada rasa yang normal) adalah lebih lama dan signifikan dengan bupivacain 
berbanding ropivacain. Jangkamasa bius motor walaubagaimanapun adalah lebih cepat 
dengan ropivacain berbanding bupivacain. Kajian mendapati terdapat perbezaan didalam 
perubahan tanda-tanda vital tetapi perubaban bukanlah konklusif Kesimpulannya, kajian ini 
telah berjay membuktikan yang penggunaan ropivacaine lebih baik dari bupivacain dari segi ia 
lebih cepat bertindak, jangkamasa pemblokan motor yang lebih pendek walaupun rasa 
kebasnya adalah lebih pendek dari bupivacain dengan ini ia tidaklah boteh menjadi ajen yang 
lebih baik dari bupivacain sebagai ubat penaban sakit selepas pembehan yang baik. Tidak ada 
sebarang komplikasi serius berlaku semasa kajian dijalankan. 
ABSTRACT 
THE USE OF ROPIV ACAINE AND BUPIV ACAINE IN 
SUPRACLAVICULAR BRACHlAL PLEXUS BLOCK 
ANY DIFFERENCE? 
xu 
An intetventional study of one year and two months duration of patients undergoing 
upper limb surgery in University Science Hospital, Kubang Kerian. A comparative study of 
local anaesthetic, ropivacaine and bupivacaine used for regional block, supraclavicular 
bracbial plexus block. 
General anaesthesia is not free from complications. The continuous search for a better 
regional anaesthesia agent is important because of issues such as blood loss, deep vein 
thrombosis, postoperative lung complications and confusion in elderly are avoided. 
This study initially involved 64 patients. 4 patients were dropped out because of fail 
block and anxiety. These patients undergone various operations of the upper extremity from 
1st November 1999 to 31st December 2000. They were admitted either in orthopaedic or 
surgical ward. All of them were elective cases with medical status ASA 1-2, age ranged from 
14 to 50 years old. 
All the patients received a standard technique of supraclavicular brachial plexus block 
using the classic technique with the aid of nerve stimulator. They were then assess for the 
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onset of sensory and motor block, the duration of the block and the changes in the vital sign. 
Other complications was also noted. 
This study found that the onset of sensory block, particularly the onset of complete 
pain relief and numbness is much faster and statistically significant for ropivacaine. The 
onset of sensory block was also found to be much faster than the onset of motor block for 
ropivacaine. This prove the claims that this agent has more preference to the sensory nerve 
fibber than the motor fibber. However the study fail to find any difference in the onset of 
motor block between both agents. The duration of analgesia (onset of first pain felt, onset of 
severe pain, duration to first loss of numbness and the duration to complete normal sensation) 
is significantly longer with bupivacaine than with ropivacaine. The duration of motor block 
was shorter with ropivacaine than with bupivacaine. There were difference in the change of 
the vital signs but the finding is not conclusive. In conclusion, this study prove the advantage 
of using ropivacaine for faster onset and shorter duration of motor block even though faster 
offset will not be a better postoperative pain relief than bupivacaine. No serious complication 
happened during the study. 
1 
INTRODUCTION 1 
1.1 PERIPHERAL NERVE BLOCK 
Regional anesthesia for surgery of the extremities is not a new idea. Extremity 
amputations were perfonned after surgical exposure of the brachial plexus or femoral 
sciatic nerves and application of cocaine before the turn of the century. During those 
days not few complications occurred due to systemic as well as local effect of the drug. 
With the great advances in general anesthesia during the first half of this century 
enthusiasm for regional anesthesia decreased. It subsequent resurgence is due to 
effective new local anesthetic, improvement in block equipment, and the proliferation 
of anesthesia residency program. The gruesome realities of war were actually 
responsible for reestablishment of the safety and efficacy of regional anesthesia for 
combat casualties. Recently introduced techniques for combined operative anesthesia 
and post-operative analgesia, new local anesthetic present an exiting scenario for 21st 
century anesthesiologist. The continuous search for a better regional agent is very 
important because of issues such as blood loss, deep vein thrombosis, post operative 
lung complication and confusion in elderly patient outweigh the regional block as 
compared to general anesthesia. 
Many research has been done before on the new enantiomer ofbupivacaine but 
mostly about the epidural route administration. The hyperbaric ropivacaine is 
found to be as half potent and equipotent doses has similar profile to hyperbaric 
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bupivacaine but with a higher incidence of side effect e.g. back pain. The relative 
potency ofropivacaine is less than bupivacane and about 0.6 as potent as bupivacaine . 
The motor block appears to be shorter with ropivacaine which allows early 
mobilization but with a good control of postoperative intravenous patient -controlled 
analgesia with morphine. This is very important as an ideal anesthetic agent because 
the risk of developing deep vein thrombosis can be avoided. The use in intravenous 
anesthesia was found to be comparable with lignocaine but has longer lasting effect. 
The search of the suitable dose for regional block has been done. Hickey et. al. 
1991a demonstrate that ropivacaine 0.5% and bupivacaine 0.5% appeared equally 
effective in providing brachial plexus anesthesia. Klein et. al. 1998 compare 0.5% 
bupivacaine , 0.5% ropivacaine and 0.750/0 ropivacaine for interscalene brachial plexus 
block demonsrate a similar efficacy between equal concentration of ropivacaine and 
bupivacaine and increasing concentration of ropivacaine from 0.5% to 0.75% fails to 
improve the onset or duration of the block. 
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1.2 OBJECTIVES 
1.2.1 General objective: 
To determine the difference between bupivacaine 0.5% and ropivacaine 0.75%, 
the onset, duration and quality of brachial plexus block. 
1.2.2 Specific Objective: 
To determine the difference between bupivacaine 0.5% and ropivacaine 0.75% in 
brachial plexus block concerning: 
1. The onset of sensory and motor block 
2. The duration of the block 
3. The quality of the regional block given 
4. The effect on the vital sign i.e. heart rate and blood pressure 
5. The effect of sedation 
6. Other associated side effect 
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1.3 HYPOTHESIS 
Null hypothesis - There is no difference between ropivacaine 0.75% and bupivacaine 
0.5% in supraclavicular block in tenns of; 
1. The onset of sensoty and motor block 
2. The duration of regional block 
3. The change in vital sign i.e heart rate(HR) and blood pressure(BP) 
4. Other complication 
1.3.1 VARIABLES: 
Independent variables: 
1. Different group of agent for brachial plexus block. 
2. Time to onset of sensoI)' and motor block 
3. Duration of sensoI)' or motor block. 
4. Percentage of patient. 
Dependent variables: 
1. Change in the vital sign, heart rate (HR) and blood pressure (BP) after block 
given. 
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LITERATURE REVIEW 2 
2.1. HISTORY 
Ropivacaine and bupivacaine like other local anaesthetic agents are drugs that 
are used clinically to produce reversible inhibition of excitation-conduction process in 
peripheral nerve fibers and nerve endings, and thus produce the loss of sensation in a 
circum scribed area ofthe body. 
2.1.1 BUPTVACATNE 
Like etidocaine, bupivacaine was created by a modification of an existing local 
anesthetic (mepivacaine) with the intent to create a more potent, longer duration local 
anesthetic. The duration of action of bupivacaine exceeds lidocaine by two to three 
times or more, and duration is even longer if analgesia is considered as an end point. 
These properties immediately established a niche for bupivacaine in surgical 
anesthesia. The hi gh pKa and lipid solubility limit transfer of the agent across the 
placenta to the fetus. The limitation in the placental transfer, combined with 
the selective increased potency for sensory block and also relatively decreased 
potenti al for motor block at lower concentrations, established efficacy of bupivacaine 
for obstetric anesthesia. Ironically, selective cardiac toxicity associated with 
bupivacaine has led to 0.75% bupivacaine being specifically disapproved for obstetric 
use by the U.S.Food and Drug Administration . 
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2.1.2 ROPIV ACAINE 
The concern about the potential of bupivacaine to produce cardio toxicity after 
accidental intravenous injection, has led to a search for an alternative long acting local 
anaesthetic drug. Ropivacaine has undergone considerable laboratory and clinical 
evaluation and has recently become improved for clinical use by the regulatory process 
in many parts of the world. Ropivacaine is the newest addition to the clinical options 
for the regional anesthesia. As with many of the newer amino amides, ropivacaine was 
designed by modification of the existing local anesthetic to achieve a clinical objective. 
Ropivacaine is a member of pipecolyl xylide (PPX) family and is chemically very 
similar to bupivacaine and mepivacaine. This is due to it belongs to the same chemical 
series as mepivacaine and bupivacaine, being intermediate between the two agents. All 
the compounds in the series contain an asymmetrical carbon atom which means that 
they may exist (and are usually presented) as a racemic mixture of two, optically active 
isomers. The motivation for designing ropivacaine came from the observation that 
toxicity with mepivacaine was most often central nervous system (eNS) toxicity and 
though rarely caused morbidity, whereas the toxicity with bupivacaine was often 
serious cardiac toxicity. 
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Although ropivacaine was first synthesized at approximately the same time as 
bupivacaine, it did not receive attention as a potential clinical agent until cardiac 
toxicity ofbupivacaine became apparent, and the objective of a possible replacement 
for bupivacaine became appealing (Carpenter 1996). The goal was to create an agent 
with the favorable properties of bupivacaine (long acting block, motor sparing at lower 
concentrations) with a toxicity profile that was more similar to mepivacaine. Because 
the difference between mepivacaine and bupivacaine is one-carbon substitution 
(methyl) on the tertiary amine for mepivacaine and four-carbon substitution (butyl) at 
the same site for bupivacaine, attempting to achieve this goal by shortening this 
aliphatic chain was logical. The three-carbon substitution (isopropyl) is the substitution 
that creates ropivacaine (figure 2.1). An experimental molecule with five carbons was 
created and further established the impetus for development of ropivacaine, because the 
result was much more potent and considerably more cardiotoxic than bupivacaine. 
Much of the early work during the clinical trials leading to the release of 
ropivacaine for general clinical use focused on achieving a clinical profile similar to 
bupivacaine with less cardiac toxicity. The results of the clinical trials were promising 
and the U.S.Food and Drug Administration released ropivacaine for sale in 1996. 
Ropivacaine is a chiral drug; in its production ropivacaine is unique in that it is 
marketed as an almost pure solution of the S isomer. This isomer was chosen because 
it is the longer acting of the two when used as a nerve blockade in animals. 
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2.1.3 PREPARATIONS 
Most local anesthetics including ropivacaine and bupivacaine are bases that are 
almost insoluble in water. Consequently, their hydrochloric salts, which are extremely 
water soluble, are usually dissolved in modified isotonic Ringer's solution. The 
preservative helps to maintain the stability of local anaesthetic solution, while the 
fungicide (usually a small concentration of thymol) prevents the growth of 
contaminating fungi. Plain bupivacaine is mildly bactericidal at room temperature 
(Sakuragi et al. 1997). Solutions of local anaesthetic are extremely stable and are 
usually have an effective shelf life of more than 2 years. Bupivacaine is prepared in the 
hydrochloride liquid state, from 0.25-0.75%, with a pH of 5.5-6.0 and pKa of 8.1. 
Whereas ropivacaine is prepared in liquid, hydrochloride salt, pH 5.5-6.0, with pKa of 
8.1 and commercially available concentrations are between 0.25% and 1.00%. 
2.1.4 CHEMICAL AND PHYSICOCHEMICAL PROPERTIES 
In common, an local anesthetics consist of lipophylic aromatic group (R1), an 
intermediate ester (-CO.O-) or amide (-NH.CO-) chain, and a hydrophilic secondary or 
tertiary amine group (R2). The intermediate chain is an important determinant of the 
duration of action; it also allows local anesthetics to be classified as esters or amides. 
Our local anesthetics of concerned come from amide group. From this group are other 
local anesthetics such as; 
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Amide local anesthetics include; 
1. Lignocaine 
2. Mepivacaine 
Whereas ester local anaesthetic include; 
1. Cocaine 
2. Procaine 
3. Chloroprocaine 
4. Amethocaine 
Figure 2.1 The chemical structure ester and amide local anaesthetic concerned are 
as below. 
Procaine 
Amide 
Ropivacaine 
Bupivacaine 
Ring Structure chain Amine 
H2N (> i COOCH2CH2 
CH3 l C3H7 
r-< I I I ~ NHCO-----;...: .. :::::.1--0 
'cH3J 
/ H3 1 I cr9 
OjNHCoi'ej 
~ ~ 
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The difference between these two groups are esters are relatively unstable in 
solution, and are rapidly hydrolyzed in the body by plasma cholinesterase, as well as 
some other esterases. By contrast, our local anesthetics of interest come from amide 
group which is relatively stable in solution, and slowly broken down by amidases in the 
liver. In addition, hypersensitivity reactions to amide local anaesthetic are almost 
unknown. 
Modification of the chemical structure may have a profound effect on their 
physicochemical characteristics. In particular, anaesthetic properties may be modified 
by changes in: 1) lipid solubility; 2) plasma and tissue protein binding; and 3) the 
dissociation constant (pKa) value. Values for these constants in ester and amide local 
anesthetics are shown below. 
The close correlation between lipid solubility and anaesthetic potency 
presumably due to lipid solubility reflect the ability of local anaesthetic to penetrate 
perineural tissues and the neuronal membrane, and reach their site of action in the 
axoplasm. For instance, in most clinical situations bupivacaine is approximately four 
times as potent as lignocaine and ropivacaine probably 314 as potent as bupivacaine. 
Plasma and tissue protein binding primarily affect the duration of action. For 
example, procaine (which is not extensively bound to plasma protein) has a short 
duration of action; by contrast, bupivacaine and ropivacaine are extensively bound and 
have prolonged effects, whereas lignocaine are moderately bound to plasma and tissue 
proteins and have intennediate duration of action. 
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The dissociation constant (pKa value) is the important factor affecting their 
rapidity and onset of action. In order to produce their effect, local anaesthetic must 
diffuse across the nerve sheath and the neuronal membrane in the form of non-ionized 
and uncharged freebase. By using the equation: 
pKa-pH = 10gIO (BH+) 
(B) 
For example, lignocaine has pKa value of approximately 7.7; at pH 7.4, 33% is present 
in solution as the non-ionized base B, and is available to diffuse across the nerve 
sheath. In contrast, bupivacaine and ropivacaine have a pKa value of 8.1; at pH 7.4, 
only 17% of these drugs are present in solution as non-ionized base B, and are available 
for diffusion. This means that the onset of action is slower for ropivacaine and 
bupivacaine and more rapid for lignocaine. 
Table 2.1 Physicochemical properties and phannacological effects 
Lignocaine 
Ropivacaine 
Bupivacaine 
PKa value relative 
7.7 
8.1 
8.1 
Lipid 
solubility 
150 
400 
1000 
relative protein onset of duration 
potency binding action of action 
2 65 fast tnoderate 
6 94 moderate long 
8 95 moderate long 
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Most of the ester local anesthetics (e.g. procaine, chloroprocaine, and 
amethocaine) as well as lignocaine are achiral compounds; in contrast, most of the 
amides are chiral, drugs. Many chiral drugs (e.g. prilocaine, mepivacaine, bupivacaine 
and etidocaine) are commonly administered clinically as a racemic mixture of two 
stereoisomers. Ropivacaine that is more recently developed is used as an s (-) 
enantiomer. Although individual enantiomers of chiral compounds have approximately 
equal local anaesthetic activity, the s-enantiomers may have important advantages in 
other respects. For example, they may produce enhanced vasoconstriction and thus 
prolong local anaesthetic activity; they may reduce the intensity and duration of 
blockade and may be associated with reduced risk of cardio toxicity. 
2.1.5 MODE OF ACTION 
Most local anaesthetic agents including ropivacaine and bupivacaine are tertiary 
amine bases (B) and administered as water-soluble hydrochlorides (B-HCL). After 
injection, the tertiary amine base is liberated by the relatively alkaline pH of tissue 
fluid: 
B.HCI + HC03-
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Consequently, in tissue fluid the local anaesthetic is present in both a non-
ionized (B) an ionized (BH+) form; their relative proportions will depend on the pH of 
the solution and the pKa of the individual compound, as determined by the modified 
Handerson-Hasselbalch equation. 
pKa - pH = log 10 (BH+) 
(B) 
The non-ionized base B then diffuses through the nerve sheath, perineural tissues and 
neuronal membrane to reach the axoplasm, where it partially ionizes; 
B + H+ +BH+ 
In the ionized form BH+, local anaesthetic enters the sodium channel from the 
axoplasm (i.e from the interior of the nerve fiber); it either occludes the channel, or 
combines with the receptor that results in channel closure. The sodium channel itself 
may be the receptor for local anesthetics, or there may be multiple binding sites for 
drugs in the sodium channel. The diffusion of the drugs through open ion channels is 
required for local anesthetics to reach their site of action. 
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2.1.6 PHARMACOKINETIKS 
Significant absorption of local anesthetics occurs from their site of injection. 
For each individual drug, the amount of local anaesthetic absorbed and the peak plaslna 
concentration will be dependant on the dose, and may be modified by the presence or 
absence of a vasoconstrictor (particularly during infiltration or conduction anaesthesia). 
The site of injection is also important; for example, higher blood levels are attained 
after intercostals and caudal blockade. Thus every 100mg lignocaine injected in an 
adult, the peak venous plasma concentration ranges from 1.5 mcg/ml (intercostals 
blockade), 1.2 mcg/ml (caudal and paracervical blockade), 1.0 mcg/ml (epidural 
blockade), 0.6 mcg/ml (brachial plexus blockade) to 0.4 mcg/ml (intrathecal blockade). 
The range of concentrations is mainly due to differences in vascularity, although other 
factors (e.g. uptake by tissue lipids) may also be involved. Therefore adherence to dose 
limits for local anesthetics may obscure potential differences in systemic toxicity, 
depending on the site of injection. 
The rate of uptake is related to the surface area available for absorption (e.g. 
extremely rapid when topical local anaesthetic sprays are applied to the 
tracheobronchial tract). The inherent effect on vascular smooth muscle-tone also 
affects the rate of absorption. In the concentrations present clinically, they may all 
produce some degree of vasodilatation, usually in the order procaine > prilocaine > 
lignocaine> mepivacaine > bupivacaine > ropivacaine. 
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After intravenous injection, the plasma concentration of all local anaesthetic 
usually declines in biexponential manner. There is an initial rapid distribution phase 
(half-life = 1-3 min) associated with their rapid uptake by highly perfuse organs (e.g. 
lung, liver and kidney, as well as skeletal muscle). Subsequently, there is a slower 
decline in plasma concentration; this phase represents the removal of local anaesthetic 
by metabolism and excretion. The elimination half-life of amides ranges from 100 min 
(lignocaine) to 160 min (bupivacaine) as compared to relatively short (approximately 
10 min) for most esters due to rapid hydrolysis by plasma esterases. The volume of 
distribution of ropivacaine and bupivacaine or in general, amide local anaesthetic is 
rather greater than total body water, while plasma clearance is comparable with liver 
blood flow. 
The binding of local anaesthetic by plasma proteins may also affect their 
pharmacokinetic behavior and pharmacodynamic effects. In general, ester local 
anesthetics are not significantly bound by plasma proteins (i.e. 5-10% or less). In 
contrast, amide local anaesthetic are mainly bound by aI-acid glycoprotein, in the order 
bupivacaine > ropivacaine > mepivacaine > lignocaine> prilocaine. The extent of 
plasma protein binding ranges from 55% to 95%~ it is usually reversible, and does not 
appear to limit or restrict the uptake of local anaesthetic by most tissue or organs. In 
certain physiological and pathological condition e.g. pregnancy, infancy, old age, 
myocardial infarction, renal failure, malignant disease and after the operation, this 
protein is increased therefore plasma protein binding is increased, free (unbound) 
concentration of drugs is reduced, and the total plasma concentration of local 
anesthetics may not be related to their effective concentration. 
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2.1.6.1) PHARMACOKINETICS OF BUPIVACAINE COMPARE WITH 
ROPIV ACAINE FROM PREVIOUS STUDIES 
The phannacokinetics ofropivacaine and bupivacaine were detennined in dogs 
after IV and epidural administration by Arthur et.alI988. After IS-minute N infusions 
of 30 mg/kg ropivacaine (n=6) and 3.4 mglkg bupivacaine (n=4), the maximum arterial 
concentrations (Cmax) of ropivacaine 2.41 +/- 0.52 micrograms/ml compared with 3.35 
+/- 0.16 microgram/ml of bupivacaine. The elimination half-life (t1l2 beta) of 
ropivacaine (25.9 +/- 1.7 min) was significantly shorter than for bupivacaine (39.1 +/-
13.3 min) after IV infusion. This was reflected by mean clearance values (CI) for 
ropivacaine of 41.1 +/- 8.2 ml/min/kg compared with 32.3 +/- 4.8 mllminlkg for 
bupivacaine, although the difference was not statistically significant. After epidural 
injections (ropivacaine n=6, bupivacaine n=5), a dose-related increase in Cmax was 
observed with both drugs. Although Cmax tended to be higher for ropivacaine, a 
significant difference was only attained when comparing Cmax after administration of 
0.25% plain solution of both agents. The addition of epinephrine did not consistently 
decrease the Cmax of either agent. The apparent t~ beta of both agents was 
significantly longer after epidural administration than after IV administration. No 
differences existed between ty; beta values for ropivacaine and bupivacaine after 
epidural administration. Total body clearance of both agents tended to be lower after 
epidural administration, particularly with epinephrine-containing solutions was 
employed. Little difference existed between the two drugs when equivalent solutions 
were administered. 
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Ekstrom et.al. 1996 found that ropivacaine is predominantly eliminated by 
extensive metabolism in the liver, with only 1 % of the dose being excreted unchanged 
in the urine of humans. They identified four metabolites formed in human liver 
microsomes, which are 3-0H-ropivacaine, 4-0H-ropivacaine, 2-0H-methyl-
ropivacaine, and 2',6' -pipecoloxylidide (PPX). The enzymes involved in the human 
metabolism of ropivacaine have not been identified. To ascertain which forms of 
cytochrome P450 are involved, they incubate ropivacaine with human microsomes 
from 10 different livers having different cytochrome P450 activities. A strong 
correlation was found between the formation of 3-0H-ropivacaine and CYPIA and 
between the formation of 4-0H-ropivacaine, 2-0H-ropivacaine, and PPX and CYP3A. 
Therefore cytochrome P450 lA and 3A are found to be responsible in the metabolism 
of ropivacaine in human liver microsomes. 
2.1.7 J\,1ET ABOLISM AND EL1M1NATION 
The metabolism of local anaesthetic is determined by their chemical structure. 
Plasma cholinesterase and other esterase enzymes in certain tissues break down ester 
local anesthetics. 
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2.1.7.1) BUPIV ACAlNE 
Bupivacaine is the most complex of the pipecolyl xylide (PPX) family. 
Because of the size of the two sides of this amphipathic molecule, hydrolysis of the 
amide linkage does not occur. Because of the large molecular weight and high level of 
lipid solubility, very little bupivacaine is excreted intact in urine, unless the urine is 
aggressively acidified. 
The first step in elimination of bupivacaine is biotransformation of the 
piperidine ring. Dealkylation creates PPX, the same by-product that results from 
dealkylation of the piperidine ring of mepivacaine. The rate of biotransformation is 
much slower than with mepivacaine. Much of PPX is excreted unchanged in the urine, 
and the remainder is slowly biotransformed by hydroxylation. The toxicity of PPX is 
less than 10% of the parent molecule, and accumulation of the primary metabolite is 
not a major component of toxicity. With large, repeated doses of bupivacaine, 
metabolites increases, and half-life of bupivacaine can increase, with net effect of 
accumulation (Dauphin et al. 1997). During sustained infusions, the total amount and 
the free fraction in the plasma increase in a linear manner with total dose (Emaneulsson 
et al. 1995). Because plasma clearance is not changed, accumulation does not increase 
in comparison to lidocaine or mepivacaine (Mather et aI, 1971). Continuous infusion 
into interscalene brachial plexus by catheter can be achieved with sustained analgesia, 
without linear increases in the free plasma levels for up to 48 hours (Kirkpatrick et al. 
1985). 
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Because of the high lipid solubility and protein binding of bupivacaine, drugs 
that are also highly protein bound, such as diazepam, have the potential to displace 
bupivacaine from binding sites. This increases the free plasma levels and slightly 
increases the rate of hepatic extraction, but, the larger unbound fraction increases the 
rate of entry into organ in which toxicity can occur (i.e., central nervous system (eNS), 
myocardium). The converse is equally true. Because bupivacaine has such a strong 
potential for protein binding, plasma levels ofbupivacaine displace other, less protein-
bound agents from binding sites, increasing their plasma level. This must be 
considered when mixtures of local anesthetics are used, because bupivacaine protein 
binding decreases the protein binding of other local anesthetics, such as mepivacaine, 
increasing their plasma levels (Hartrick et a1. 1984). Drugs that prolong the 
metabolism or decrease hepatic clearance of bupivacaine also increase plasma levels. 
H2 blocker do not decrease the plasma clearance ofbupivacaine, even though they have 
an effect on lidocaine, perhaps because of the high lipid solubility and low hepatic 
extraction rate with bupivacaine (O'Sullivan et a1. 1988). When clonidine was given to 
mice before administration of bupivacaine, decreased hepatic metabolism occurred 
(Bruguerolle et a1. 1995). 
2.1.7.2 ROPIVACAINE 
Like bupivacaine, the large aromatic and amine poles of ropivacaine protect the 
amide bond from hydrolysis. Because of high level of lipid solubility and molecular 
weight, almost no ropivacaine is excreted intact in the urine is aggressively acidified. 
Virtually the entire metabolism occurs in the liver (Rutten et a1.1990). 
Biotransformation begins with dealkylation by mixed-function liver oxidases of the 
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piperidine ring to PPX, and subsequently follows a path to elimination similar to the 
path that PPX takes during metabolism of mepivacaine and bupivacaine (Oda et al. 
1995). The rate of this first step is intermediate between ropivacaine two relatives 
(mepivacaine and bupivacaine), but closer to bupivacaine (Lee et al. 1989). Hence, the 
metabolic half-lives ofbupivacaine and ropivacaine are very similar. Like bupivacaine, 
ropivacaine has potential for cumulative effect when infusion rate exceeds the rate of 
biotransformation and elimination. Although the total plasma concentration of 
ropivacaine increased with time during postoperative infusion for analgesia after 
orthopaedic surgery, the free plasma fraction stabilized within the initial 24 hours at 
level well below toxic (Burm et al. 1997;Erichsen et al. 1996). After an established 
epidural level, continued analgesia with ropivacaine is not associated with increases in 
free plasma fraction of the agent or with levels that reach the toxic range (Scott et al. 
1997). The increased plasma fraction may be related to the weaker binding of 
ropivacaine to plasma proteins (compared to bupivacaine), which is also responsible for 
the higher level of free plasma fraction ropivacaine found in the fetus shortly after 
injection into pregnant sheep (Santos et al. 1990). 
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2.2 PROPERTIES FOR CONDUCTION BLOCK 
2.2.1 BUPN ACAINE 
With a high pKa and high level of protein binding, the latency to onset of 
conduction block for bupivacaine is the longest of all available local anesthetics. Early 
evidence of onset is usually apparent 20 minutes after injection into the epidural space 
or peripheral nerve site. Complete block is usually present by 30 minutes. Sensory 
block is usually excellent with bupivacaine, even at lower concentrations. Duration of 
complete anesthesia is long, with motor function returning first. At full doses, 
bupivacaine can occasionally produce conduction block with 24 hours duration or 
greater, without neural injury as the mechanism (Madej et al. 1987). At very low 
concentrations (less than 0.25%), sensory anesthesia and analgesia separate, and 
achieving analgesia without complete motor block if possible. 
The sympathetic block that is achieved with bupivacaine is related to central 
axis activity and not plasma levels, because comparable sympathetic changes do not 
occur at the same plasma levels achieved by parenteral administration (Malmqvist et al. 
1989). During scoliosis surgery, somatosensory evoked potential can be recorded from 
the posterior tibia nerve as long as the concentration of epidural bupivacaine is 0.25% 
or lower (Loughnan et al.1995). Differential block with bupivacaine for different fiber 
types (Gisses et al. 1982; Palmer et a1.1983), either within the spinal column (Dietz and 
Affe 1997a). The effect also occurs in vitro (Rosenberg et al. 1980). 
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The clinical observations are supported by in vitro work with isolated rabbit 
vagus nerve, which shows sensory block comparable to that of bupivacaine with a 
decreased potency for motor fibers after administration of ropivacaine (Bader et al. 
1989; Reynolds 1991). Ropivacaine is less soluble in fat than bupivacaine. This may 
explain why less potency for A-fiber block exists (motor) in intact nerve preparations, 
whereas potency for C fibers (sensory) is identical, because A fibers are contained 
within intact nerves, which contain a considerable amount of fatty tissue (Rosenberg et 
al. 1986). The high level of lipid solubility and protein binding limit the movement of 
ropivacaine through tissues (as with bupivacaine), increasing the need for anatomic 
accuracy of injection with regional anesthetic procedures. In rats, ropivacaine 
produced a longer duration of sciatic block with less toxicity than bupivacaine (Kohane 
et a1.1998) 
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.2.3 EFFECT OF ADPITION OF EPINEPHRINE TO PHARMACOKINETIC 
PROPERTY 
Epinephrine has very little effect on the duration of action of ropivacaine 
(Cederholm et al. 1994b). Epinephrine does not delay the interval to maximum plasma 
level or decrease the absolute level achieved (Hickey et al.1990b) . They did a study to 
detennine the phannacokinetic properties of ropivacaine used with or without 
epinephrine for perivascular brachial plexus block. They measured the plasma 
concentration of ropivacaine in peripheral venous blood samples taken for 12 hours 
after drug administration. The mean peak plasma concentration (Cmax) was 1.6 +/- 0.6 
mgIL and 1.3 +/- 0.4 mgIL after administration of ropivacaine with and without 
epinephrine. The median time to peak plasma concentration (tmax) was 0.75 hr and 0.88 
hr and the mean area under the plasma concentration curve AUCO-12h was 7.7 +/- 3.6 
and 7.0 +/- 3.4 mg.1lhr. The differences were found not statistically significant. 
Therefore they concluded that the addition of epinephrine does not alter the 
pharmacokinetic properties of ropivacaine when used for subclavian perivascular 
brachial plexus block. Motor block duration is not increased by addition of epinephrine 
(Feldman and Covino 1988). Increasing the concentration ofropivacaine (from 0.5% 
to 1.0%) increased the duration of sensory block as well as of motor block, when the 
agent administered in the epidural space (Finucane et a1. 1996). 
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2.4 TOXICITY 
2.4.1 BUPIV ACAINE 
The maximum recommended dose for bupivacaine is the lowest of all the 
available local anesthetics at 1-2 mglkg. Epinephrine added to bupivacaine decreases 
the plasma levels achieved and increases the time interval to maximum level (Bunn et 
aI.1986). One unique aspect of bupivacaine is diminished or absent clinical signs of 
accumulation of bupivacaine in the plasma that occurs until plasma protein-binding 
sites are fully occupied. In many patients, the aura of CNS toxicity does not occur at 
all with bupivacaine (Friedman et al. 1982; Yamashiro 1977). Although convulsion 
proceeded cardiovascular collapse with intravenous bupivacaine in dogs (Liu et al. 
1983) and monkeys (Munson et al. 1975) studied, this may not be the case in all 
humans, especially if premedicated. The systemic signs are related to the free plasma 
fraction, which remains extremely low until the binding sites are fully occupied. When 
no more sites for protein binding are available, the free fraction in the plasma rises 
rapidly, and the toxicity can occur. The time interval between rapid rise and abrupt 
onset of major toxicity is narrow, which decreases the aura ofCNS toxicity that occurs 
with other local anesthetics. Among the most lipid-soluble agents, rapid administration 
of bupivacaine caused eNS changes later than a comparable rate of administration of 
etidocaine (Malagodi et al. 1977). The value of benzodiazepines in the prevention of 
convulsion with bupivacaine is not clear; their use in the prompt treatment of early 
signs of generalized convulsions is more unequivocal. When benzodiazepines are used 
to raise the seizure threshold or for anxiolysis, they can displace bupivacaine from 
protein-binding sites and abruptly increase the free plasma fraction, suddenly 
